Yawning has an unusual and unexpected effect on the flow of fluid protecting the brain, a recent study reveals, though it's ...

Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology -HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals ...

DelveInsight's Oncolytic Virus Competitive Landscape 2026 report provides comprehensive global coverage of pipeline oncolytic ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the presentation of four ...

A report that was jointly produced by the Canadian Centre for Policy Alternatives and the Parkland Institute finds Alberta's ...

As Jammu and Kashmir is racing for the budget estimate announcements next week, Masood Hussain offers an idea of hopes and ...

Axon Neuroscience’s active tau immunotherapy, AADvac1, has been selected as the first tau-targeted therapy to enter a ...

The oncolytic virus therapy landscape has expanded steadily over the past decade, with over 100 companies worldwide pursuing clinical or preclinical programs. A few leaders, such as Candel Therapeutic ...

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...

Key HighlightsMotixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease and beta-thalassemia enabling accelerated access to gene therapies73% ...

CURE SYNGAP1, a 501(c)(3) organization, is proud to announce the award of a $25,000 grant to Dr. Àlex Bayés Puig, Group ...

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 1 ...